Double-Digit Growth in Sales, Operating Profit, and Net Profit
Highest First-Half Sales on Record

Centellian24 Second-Quarter Sales Surge 566 Percent
Health Functional Foods Business Grows Over 40 Percent

Dongkook Pharmaceutical announced on August 14 that its consolidated sales in the first half of this year reached 509.9 billion won, with operating profit at 53.4 billion won and net profit at 43.6 billion won. Compared to the same period last year, these figures increased by 11.5%, 12.6%, and 20.9%, respectively, marking the highest first-half sales in the company’s history.


On a standalone basis, sales were 436.5 billion won, operating profit was 47.8 billion won, and net profit was 40.8 billion won, representing year-on-year increases of 16.7%, 23.4%, and 32.9%, respectively.

Dongkook Pharmaceutical company logo image. Dongkook Pharmaceutical

Dongkook Pharmaceutical company logo image. Dongkook Pharmaceutical

View original image

By business segment, the prescription drug (ETC) business grew by 10.5% year-on-year in the second quarter, with a cumulative first-half growth rate of 9.4%. The over-the-counter (OTC) business also continued to grow, backed by the expansion of brand product lines and a broader general product portfolio.


In the health and beauty segment, the dermacosmetics brand ‘Centellian24’ continued its growth trend. Centellian24’s second-quarter sales increased by 566% compared to the same period last year. As of June, accumulated sales of its flagship product, 'Madeca Cream,' have surpassed 99 million units.


Sales from the health functional foods business in the first half increased by more than 40% year-on-year. 'Myfit' has recorded approximately 47 billion won in cumulative sales since its launch.

The company is also expanding its global business. For example, ‘Uresco’, a combination drug for benign prostatic hyperplasia, has secured a license and supply contract worth a total of 3.9 billion won over the next 10 years with Spanish pharmaceutical company FAES FARMA, covering 13 countries in Central and South America.



Dongkook Pharmaceutical plans to expand its pipeline of new products and businesses through pharmaceuticals developed with DDS (Drug Delivery System) technology and open innovation.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing